Life expectancy in hereditary cancer predisposing diseases: An observational study

Journal of Medical Genetics

Volumn 49, Issue 4, 2012, Pages 264-269

  Wilding, Anna ^a   Ingham, Sarah Louise ^a   Lalloo, Fiona ^a   Clancy, Tara ^a   Huson, Susan M ^a   Moran, Anthony ^b   Evans, D Gareth ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BASAL CELL NEVUS SYNDROME; BENIGN TUMOR; CANCER SURVIVAL; CAUSE OF DEATH; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL CANCER; FAMILIAL POLYPOSIS; HUMAN; LIFE EXPECTANCY; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SURVIVAL RATE; VON HIPPEL LINDAU DISEASE;

CAUSE OF DEATH; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84864104025     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2011-100562     Document Type: Article

References (39)

1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet 2010;152A:327e32.
2. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 1986;314:1010e15.
3. Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J. Neurofibromatosis type 1 and childhood cancer. Cancer 1993;72:2746e54.
4. Stiller CA, Chessels JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994;70:969e72.
5. Zoller MET, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumours in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125e31.
6. Poyhonen M, Niemela S, Herva R. Risk of malignancy and death in neurofibromatosis. Arch Pathol Lab Med 1997;121:139e43.
7. Lalloo F, Kerr B, Friedman J, Evans G. Risk Assessment and Management in Cancer Genetics. Oxford: Oxford University Press, 2006.
8. Zoller M, Rembeck B, Akesson H, Angervall L. Life-expectancy, mortality and prognostic factors in neurofibromatosis type 1: a twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm malignant nerve sheath tumoursenerol (stockh) 1995;75:136e40.
9. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68:1110e18.
10. Evans DG, O'Hara C, Wilding A, Ingham SL, Howard E. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial surival in a region of the UK since 1989. Eur J Hum Genet 2011;19:1187e91.
11. Mallinson EK, Newton KF, Bowen J, Lalloo F, Clancy T, Hill J, Evans DGR. The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut 2010;59:1378e82.
12. Galle TS, Juel K, Bulow S. Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 1999;34:808e12.
13. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet 2000;37:897e904.
14. Evans DG, Huson S, Donnai D, Neary N, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603e18.
15. Baser ME, Friedman JM, Aeschilman D, Joe H, Wallace AJ, Ramsden RT, Evans DG. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002;71:715e23.
16. Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II. Genet Med 2009;11:599e610.
17. Akcaglar S, Yavascaoglu I, Vuruskan H, Oktay B. Genetic evaluation of von HippeleLindau disease for early diagnosis and improved prognosis. Int Urol Nephrol 2008;40:615e20.
18. Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ, Whitehouse R, Dodd C, Lavin M, Hartley N, Super M, Evans DG. A genetic register for von Hippel-Lindau disease. J Med Genet 1996;33:120e7.
19. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151e63.
20. Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, lebovics R, Sledjeski K, Choyke PL, Zbar B, Linehan M, Oldfield EH. Endolymphatic sac tumours. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997;277:1461e6.
21. Evans DG, Ladusans E, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993;30:460e4.
22. Cowan R, Hoban P, Kelsey A, Birch JM, Evans DG. The gene for naevoid basal cell carcinoma (Gorlin) syndrome acts as a tumour supressor gene in medulloblastoma. Br J Cancer 1997;76:141e5.
23. García de Marcos JA, Dean-Ferrer A, Rodríguez SA, Calderón-Polanco J, Francisco J, Granados A, Poblet E. Basal cell nevus syndrome: clinical and genetic diagnosis. Oral Maxillofac Surg 2009;13:225e30.
24. NugentT KP, Spigelman AD, Phillips RK. Life-expectancy after colectomy and ileorectal anastamosis for familial adenomatous polyposis. Dis colon rectum 1993;36:1059e62.
25. Friedrich RE, Hartmann M, Mautner VF. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. Anticancer Res 2007;27:1957e60.
26. Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P. Prognostic factors of CNS Tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003;126:152e60.
27. Hagel C, Zils U, Peiper M, Kluwe L, Gottard S, Friedrich RE, Zurakowski D, von Deimling A, Mautner VF. Histopathology and clinical outcomes of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 2006;82:187e92.
28. Ferrai A, Bisogno G, Macaluso A, Casanova M, D'Angelo P, Pierani P, Zanetti I, Alaggio R, Cecchetto G, Carli M. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007;109:1406e12.
29. Evans DG, Baser ME, McGraughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311e14.
30. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990;113:39e52.
31. National Institutes of Health Consensus Development Conference. Neurofibromatosis conference statement. Arch Neurol 1988;45:575e8.
32. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DGR. Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759e65.
33. Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Frayling I, Friedl W, Hes FJ, Hodgson S, Jarvinen H, Mecklin JP, Moller P, Myrhoi T, Nagengast FM, Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Teipar S, Thomas HJ, Wijnen J. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57:704e13.
34. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N. Von Hippel-Lindau disease. A genetic study. J Med Genet 1991;28:443e7.
35. Joly D, Mejean A, Correas J-M, Timsit M-C, Verkarre V, Deveaux S, Landais P, Grunfield JP, Richard S. Progress in Nephron Sparing Therapy for Renal Cell Carcinoma and von Hippel-Lindau disease. J Urol 2011;185:2056e60.
36. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. NEJM 2009;361:358e67.
37. Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacod A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard H, Welling DB, Widemann B, Yohay K, Giovannini M. Consensus Recommendations to accelerate Clinical Trials for Neurofibromatosis type 2. Clin Cancer Res 2009;15:5032e9.
38. Evans DG, Bourn D, Wallace A, Ramsden RT, Mitchell JD, Strachan T. Diagnostic issues in a family with late onset type 2 neurofibromatosis. J Med Genet 1995;32:470e4.
39. Evans DG, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Brit J Neurosurg 2005;19:5e12.